🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with figures suggesting over 82 million infections per year. Notably increased rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Authorization

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a significant shift in the therapy of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Outcomes and Global Access

Based on findings published in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which involves a dual-drug approach. The research enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in many regions with limited resources.

Doctors on the front lines have voiced positive views. Having a single-dose, oral treatment such as this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to reduce the burden of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.